The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901: An extension to an open-label, dose-escalation, and non-randomized phase 1 study | medRxiv

Article usage

Article usage: December 2021 to June 2022

	Abstract	Full	Pdf
Dec 2021	16002	24	3485
Jan 2022	11030	215	2082
Feb 2022	919	18	144
Mar 2022	470	22	83
Apr 2022	507	8	67
May 2022	329	45	62
Jun 2022	241	15	44

View the discussion thread.

Posted January 04, 2022.

Subject Area

Infectious Diseases (except HIV/AIDS)

Subject Areas

All Articles

Addiction Medicine (174)
Allergy and Immunology (419)
Anesthesia (97)
Cardiovascular Medicine (894)
Dentistry and Oral Medicine (166)
Dermatology (101)
Emergency Medicine (257)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
Epidemiology (8745)
Forensic Medicine (4)
Gastroenterology (403)
Genetic and Genomic Medicine (1845)
Geriatric Medicine (175)
Health Economics (386)
Health Informatics (1282)
Health Policy (642)
Health Systems and Quality Improvement (489)
Hematology (206)
HIV/AIDS (387)
Infectious Diseases (except HIV/AIDS) (10521)
Intensive Care and Critical Care Medicine (564)
Medical Education (193)
Medical Ethics (52)
Nephrology (216)
Neurology (1744)
Nursing (100)
Nutrition (264)
Obstetrics and Gynecology (342)
Occupational and Environmental Health (457)
Oncology (959)
Ophthalmology (279)
Orthopedics (107)
Otolaryngology (174)
Pain Medicine (117)
Palliative Medicine (41)
Pathology (262)
Pediatrics (553)
Pharmacology and Therapeutics (264)
Primary Care Research (218)
Psychiatry and Clinical Psychology (1836)
Public and Global Health (3963)
Radiology and Imaging (649)
Rehabilitation Medicine and Physical Therapy (340)
Respiratory Medicine (532)
Rheumatology (214)
Sexual and Reproductive Health (178)
Sports Medicine (165)
Surgery (196)
Toxicology (37)
Transplantation (105)
Urology (78)